Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Welcome to the POTP board, the DPP-IV company -- Ignore unavailable to you. Want to Upgrade?

To: former_pgs who wrote (8)	8/3/2006 11:30:48 PM
From: kenhott	Respond to of 90

Interesting and long. Thanks NR_FPGS. Everyone can see the CRs of course. Scanning I see they went with single agent and a combo w/ cisplatin at 100/m2 for phase 2s melanoma which strikes me as a little strange. I'd scanned the management profile. Are they good enough to pull this off would be one of my questions. Off the top thoughts only.

To: former_pgs who wrote (8)	8/4/2006 12:05:29 AM
From: rareearth42	Read Replies (1) \| Respond to of 90

Thanks f_pgs, very helpful. For me, the comment that the CRs were durable is very important. One could imagine Talabostat decreasing the tumor-associated fibrosis, yielding an apparent decrease in size by CT and an apparent CR or PR, but no real effect on the malignant cells. However if this had happened, we wouldn't expect the clinical response to be durable, as the tumors should continue to grow. Accordingly, I remain enthusiastic about POTP. RE42